Urolithin A vs Spermidine: How They Compare

Urolithin A and spermidine are both cornerstones of the 'cellular recycling' story in longevity science — but they clean up different things. One renews mitochondria specifically; the other switches on broad cellular housekeeping. Here is how they actually differ and how to choose.

The recycling analogy, and why the details matter

If you have read anything about aging biology, you have probably met the idea that cells accumulate damage and that clearing that damage helps them keep working. Both urolithin A and spermidine live in this space, which is why they are so often mentioned together. But the comparison is more interesting once you notice they operate at different scales. Urolithin A is a gut postbiotic — your microbiome makes it from ellagitannins in pomegranates, walnuts, and berries — and it specifically supports mitophagy, the recycling of worn-out mitochondria. Spermidine is a naturally occurring polyamine, found in foods like wheat germ, aged cheese, natto, mushrooms, and legumes, and it is best known as an inducer of autophagy, the cell's general-purpose program for breaking down and reusing damaged components.

Think of it this way: autophagy is whole-house cleaning, while mitophagy is the specialized crew that services just the power plants. Mitophagy is technically a subset of the broader autophagy family, but the two supplements have distinct research stories, mechanisms of entry, and evidence bases.

Mechanism, side by side

Urolithin A: targeted mitochondrial renewal

Mitochondria produce most cellular energy, and they degrade with use. When damaged mitochondria pile up faster than the cell can clear them, energy output tends to decline. Urolithin A supports mitophagy — the selective tagging and recycling of those damaged mitochondria — which helps the cell maintain a healthier mitochondrial pool. An important practical detail: only some people's microbiomes convert dietary ellagitannins into meaningful amounts of urolithin A, so a standardized dose can matter more than diet alone.

Spermidine: switching on broad autophagy

Spermidine is a polyamine your body also makes on its own, though levels tend to decline with age. In laboratory and animal studies it triggers autophagy, in part by influencing the acetylation of proteins involved in the autophagy machinery. Because autophagy touches nearly every cellular system, spermidine's proposed benefits are broad — spanning cardiovascular, cognitive, and general cellular-maintenance themes — but that breadth also makes its effects harder to pin to a single measurable outcome.

The evidence for urolithin A, organized by strength

Urolithin A stands out for having a growing base of human randomized data tied to specific endpoints, not only animal work. We separate what has been shown in people from what has only been shown in cells or animals.

Human trials (strongest evidence)

The first-in-human study by Andreux and colleagues in Nature Metabolism (2019) found urolithin A safe and well tolerated up to 1,000 mg per day, producing a mitochondrial gene-expression signature. Liu, D'Amico and colleagues in JAMA Network Open (2022) ran a roughly four-month trial in older adults and reported improved muscle endurance — more contractions before fatigue. Singh and colleagues in Cell Reports Medicine (2022) studied middle-aged adults over four months with 500 mg and 1,000 mg arms and reported gains in muscle strength and exercise performance. A 2025 Nature Aging randomized trial (about 28 days) found urolithin A supported immune-cell mitochondrial health in midlife adults, relevant to age-related inflammation. A 2024 Journal of the International Society of Sports Nutrition eight-week trial in resistance-trained men examined endurance and recovery markers, and a 2025 distance-runners trial added more exercise data.

What the reviews say

A 2024 systematic review in Ageing Research Reviews is candid that urolithin A's human evidence is still emerging — trials are relatively short and modest in size. The muscle and mitochondrial signal is consistent, but early.

Preclinical foundation (animal and cell, not human proof)

The foundational study by Ryu and colleagues in Nature Medicine (2016) showed urolithin A induced mitophagy, extended lifespan in C. elegans, and improved muscle function in rodents. D'Amico and colleagues in Aging Cell (2022) explored joint and cartilage mitochondrial health in osteoarthritis models. Early, preclinical research is also exploring skin, gut, brain, and heart pathways — but those remain animal and cell findings, not human proof.

The evidence for spermidine

Spermidine's research base leans heavily on preclinical and observational work. Much of the excitement traces to animal studies — for example, work in Circulation Research reporting that spermidine promoted cardioprotective autophagy in mice, and rodent and cell studies linking it to autophagy and longevity pathways. In humans, a good portion of the encouraging data is observational: population studies have associated higher dietary spermidine intake with cardiovascular and cognitive outcomes. Those associations are interesting but cannot establish cause and effect, because people who eat more spermidine-rich foods differ in many other ways. There have been small human trials — for instance, memory-focused pilot studies in older adults — but results have generally been modest or mixed, and the trials small. For a fuller primer, see our what is spermidine explainer.

So the honest contrast is this: urolithin A has more human randomized data pointing at defined, measurable outcomes like muscle strength and endurance, while spermidine's human case rests more on observational associations and small pilots, with its strongest mechanistic evidence in animals.

Are they complementary?

In principle, yes — and arguably more naturally than most pairings. Mitophagy is a specialized branch of autophagy, so a compound that supports broad autophagy (spermidine) and one that supports mitochondria-specific recycling (urolithin A) target overlapping but non-identical processes. Some people interested in cellular maintenance use both daily. Still, there is no large human trial testing the specific combination, so pairing them is a plausible strategy rather than a proven protocol. Autophagy and cardiovascular biology are also areas where individual circumstances matter, so if you have a heart condition, take medications, or are pregnant, talk with your doctor before starting either — neither is a treatment for any disease, and this page is education, not medical advice. For medical concerns, see your doctor.

How to choose by goal

Choose urolithin A if your priority is energy, muscle, and mitochondria

If you care most about cellular energy, muscle strength and endurance, exercise recovery, or supporting mitochondrial health with age, urolithin A has the most directly relevant human data and a well-characterized safety profile at up to 1,000 mg per day. Our urolithin A benefits and urolithin A for muscle pages go deeper.

Consider spermidine if you are drawn to broad autophagy

If your interest is whole-cell housekeeping and you are comfortable acting largely on observational human data and animal mechanism studies, spermidine is the more on-target choice. Many people appreciate the candid framing: promising and widely researched, but with a thinner base of controlled human efficacy trials than urolithin A.

Building from scratch? Start with the better-evidenced daily foundation

For most people assembling a longevity routine, a daily mitochondrial-support supplement backed by human trials is a reasonable anchor, with autophagy-focused options layered in as the evidence matures. To go deeper on urolithin A, see our complete urolithin A guide, compare formats in our best urolithin A gummies roundup, and learn the underlying biology in what is mitophagy.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.